RevvityRVTY
RVTY
About: Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
Employees: 11,500
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
154% more call options, than puts
Call options by funds: $7.52M | Put options by funds: $2.96M
73% more first-time investments, than exits
New positions opened: 83 | Existing positions closed: 48
60% more funds holding in top 10
Funds holding in top 10: 5 [Q2] → 8 (+3) [Q3]
17% more capital invested
Capital invested by funds: $11.8B [Q2] → $13.8B (+$1.98B) [Q3]
16% more repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 158
7% more funds holding
Funds holding: 478 [Q2] → 513 (+35) [Q3]
3.39% less ownership
Funds ownership: 91.1% [Q2] → 87.71% (-3.39%) [Q3]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$135
20%
upside
Avg. target
$140
25%
upside
High target
$146
30%
upside
7 analyst ratings
7 positive
100%
0 neutral
0%
0 negative
0%
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target | 23%upside $138 | Buy Upgraded | 13 Dec 2024 |
Barclays Luke Sergott 27% 1-year accuracy 13 / 48 met price target | 20%upside $135 | Overweight Maintained | 25 Nov 2024 |
TD Cowen Dan Brennan 48% 1-year accuracy 14 / 29 met price target | 28%upside $144 | Buy Maintained | 5 Nov 2024 |
Bernstein Eve Burstein 67% 1-year accuracy 4 / 6 met price target | 29%upside $145 | Outperform Maintained | 5 Nov 2024 |
Raymond James Andrew Cooper 17% 1-year accuracy 2 / 12 met price target | 30%upside $146 | Outperform Maintained | 5 Nov 2024 |
Financial journalist opinion
Based on 4 articles about RVTY published over the past 30 days
Neutral
Business Wire
4 days ago
Revvity to Present at J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) will present at the 43rd annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 8:15 a.m. PT in San Francisco, CA. President and Chief Executive Officer Prahlad Singh will provide an update on the Company and its strategic priorities. To access the presentation, a live audio webcast will be available via this page. A replay of the presentation will be posted on the Revvity Investor Relations website after the event and.
Positive
Seeking Alpha
5 days ago
Safe Biopharma: Revvity's Recurring Revenues And Diagnostics
Revvity, Inc. is a leader in life sciences and diagnostics with diversified revenue streams and a strong balance sheet, making it a low-risk biopharma play. The company's recurring revenue base (80%) from consumables, services, and software ensures predictable income and financial stability. The company has a global footprint and an estimated TAM exceeding $60 billion, showcasing its significant market opportunity.
Positive
Benzinga
1 week ago
Despite Higher Valuations, Some Life Sciences Tools Stocks Create Good Opportunities: Analyst
BofA Securities reports that the Life Sciences Tools sector struggled in fiscal year 2024.
Negative
Zacks Investment Research
2 weeks ago
Why Is Revvity (RVTY) Down 8.7% Since Last Earnings Report?
Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
1 month ago
Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced an expansion of its work with Genomics England that leverages both organizations' expertise and resources to advance critical genomic initiatives across the United Kingdom. Building on the parties' long and productive work history, this advanced collaboration is dedicated to accelerating Genomics England's renowned research programs, supporting diverse areas in genomics, and fostering talent in innovative healthcare fi.
Neutral
Business Wire
1 month ago
Revvity to Present at 7th Annual Evercore ISI HealthCONx Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), will present at the 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3, 2024, at 8:20 a.m. ET in Coral Gables, FL. Prahlad Singh, president and chief executive officer, will provide an update on the Company and its strategic priorities. To register, click here. A live audio webcast will be available on the Events section of the Company's website. A replay of the presentation will be posted on the Revvity Investor Rel.
Neutral
Business Wire
1 month ago
Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells
SAN DIEGO--(BUSINESS WIRE)--Scale Biosciences and Revvity's BioLegend launch first-of-its-kind solution for high parameter protein profiling of single cells.
Neutral
Business Wire
1 month ago
Revvity to Host Investor Day and Updates Organizational Structure to Reflect Recent Transformation
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host an Investor Day on Thursday, November 21, 2024 at 9:00 a.m. PT which will feature presentations by members of Revvity's senior management team on the Company's key business initiatives, operational achievements and future financial outlook. The Company also announced strategic adjustments to its operating model to unlock the full value of its recent transformation which will be highlighted at the upcoming.
Positive
Benzinga
1 month ago
These Analysts Revise Their Forecasts On Revvity Following Q3 Results
Revvity, Inc. RVTY reported better-than-expected third-quarter earnings on Monday.
Positive
Zacks Investment Research
1 month ago
RVTY Q3 Earnings & Revenues Beat Estimates, Guidance Revised
Revvity's third-quarter results showcase strong growth in Diagnostics business, along with a decline in Life Sciences segmental sales.
Charts implemented using Lightweight Charts™